Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: A potential benefit from infectious disease consultation

Clinical Microbiology and Infection

Volumn 21, Issue 1, 2015, Pages 79-86

  Farmakiotis, Dimitrios ^a,b,c   Kyvernitakis, A ^a   Tarrand, J J ^a   Kontoyiannis, D P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antifungal resistance; Cancer; Candida glabrata; Candidaemia; Infectious disease consultation

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ARTICLE; BLOOD CULTURE; CANCER PATIENT; CANCER SURVIVAL; CANDIDA GLABRATA FUNGAEMIA; CANDIDEMIA; CHILD; COHORT ANALYSIS; CONSULTATION; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; FEMALE; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; CANDIDA GLABRATA; CATHETER INFECTION; COMPLICATION; INFECTIOUS DISEASE MEDICINE; MIDDLE AGED; NEOPLASM; PATIENT REFERRAL; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT; VERY ELDERLY; YOUNG ADULT;

CANDIDA; CANDIDA GLABRATA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDEMIA; CATHETER-RELATED INFECTIONS; CHILD; FEMALE; HUMANS; INFECTIOUS DISEASE MEDICINE; MALE; MIDDLE AGED; NEOPLASMS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TIME-TO-TREATMENT; YOUNG ADULT;

EID: 84926334601     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.07.006     Document Type: Article

References (30)

1. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
2. Antoniadou A., Torres H.A., Lewis R.E., Thornby J., Bodey G.P., Tarrand J.P., et al. Candidemia in a tertiary care cancer center: invitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 2003, 82:309-321.
3. Hachem R., Hannah H., Kontoyiannis D., Jiang Y., Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112:2493-2499.
4. Sipsas N.V., Lewis R.E., Tarrand J., Hachem R., Rolston K.V., Raad, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115:4745-4752.
5. Alexander B.D., Johnson M.D., Pfeiffer C.D., Jiménez-Ortigosa C., Catania J., Booker R., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated MIC. Clin Infect Dis 2013, 56:1724-1732.
6. Ostrosky-Zeichner L. Candida glabrata and FKS mutations: witnessing the emergence of the true multi-drug resistant Candida. Clin Infect Dis 2013, 56:1733-1734.
7. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
8. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
9. Patel M., Kunz D.F., Trivedi V.M., Jones M.G., Moser S.A., Baddley J.W. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn Microbiol Infect Dis 2005, 52:29-34.
10. Takakura S., Fujihara N., Saito T., Kimoto T., Ito Y., Iinuma Y., et al. Improved clinical outcome of patients with Candida bloodstream infections through direct consultation by infectious diseases physicians in a Japanese university hospital. Infect Control Hosp Epidemiol 2006, 27:964-968.
11. Kim S.H., Yoon Y.K., Kim J.M., Sohn J.W. Clinical impact of time to positivity in Candida species on mortality in patients with candidemia. JAntimicrob Chemother 2013, 68:2890-2897.
12. Garnacho-Montero J., Díaz-Martín A., García-Cabrera E., Ruiz Pérez de Pipaón M., Hernández-Caballero C., Lepe-Jiménez J.A. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. JAntimicrob Chemother 2013, 68:206-213.
13. Fernandez J., Erstad B.L., Petty W., Nix D.E. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis 2009, 64:402-407.
14. Kollef M., Micek S., Hampton N., Doherty J.A., Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012, 54:1739-1746.
15. Klevay M.J., Ernst E.J., Hollanbaugh J.L., Miller J.G., Pfaller M.A., Diekema D.J. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008, 60:273-277.
16. Kludze-Forson M., Eschenauer G.A., Kubin C.J., Della-Latta P., Lam S.W. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol 2010, 48:436-439.
17. Taur Y., Cohen N., Dubnow S., Della-Latta P., Lam S.W. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010, 54:184-190.
18. Grim S.A., Berger K., Teng C., Gupta S., Layden J.E., Janda W.M., et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. JAntimicrob Chemother 2012, 67:707-714.
19. Slavin M.A., Sorrell T.C., Marriott D., Thursky K.A., Nguyen Q., Ellis D.H., et al. Candidemia in adult cancer patients: risks for fluconazole-resistant isolates and death. JAntimicrob Chemother 2010, 65:1042-1051.
20. CLSI Reference method for broth dilution antifungal susceptibility testing of yeasts 2008, M27-A3, Clinical and Laboratory Standards Institute, Wayne, PA. 3rd ed.
21. CLSI Reference method for broth dilution antifungal susceptibility testing of yeasts 2012, M27-S4, Clinical and Laboratory Standards Institute, Wayne, PA. 4th ed.
22. Raad I., Hanna H., Boktour M., Girgawy E., Danawi H., Mardani M., et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004, 38:1119-1127.
23. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Update 2010, 13:180-195. CLSI Subcommittee for Antifungal Susceptibility Testing.
24. Liu C.Y., Huang L.J., Wang W.S., Chen T.L., Yen C.C., Yang M.H., et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. JInfect 2009, 58:154-160.
25. Schoenfeld D. Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. Crit Care Med 2006, 10:103.
26. Clancy C.J., Nguyen M.H. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013, 56:1284-1292.
27. Granwehr B.P., Kontoyiannis D.P. The impact of infectious diseases consultation on oncology practice. Curr Opin Oncol 2013, 25:353-359.
28. Nucci M., Anaissie E., Betts R.F., Dupont B.F., Wu C., Buell D.N., et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010, 51:295-303.
29. Andes D.R., Safdar N., Baddley J.W., Playford G., Reboli A.C., Rex J.H., et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012, 54:1110-1122.
30. Lewis R.E., Cahyame-Zuniga L., Leventakos K., Chamilos G., Ben-Ami R., Tamboli P., et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013, 56:638-645.